
• Reported GAAP EPS of -$0.29 down -514.29% YoY • Reported revenue of $17.56B down -1.16% YoY • Pfizer reaffirms full-year 2026 revenue guidance of $59.5 to $62.5 billion and Adjusted diluted EPS guidance of $2.80 to $3.00, reflecting expected COVID-19 product revenues and LOE impact.
Bullish
Pfizer achieved strong non-COVID operational revenue growth in 2025, driven by strategic investments in R&D and business development. The company also advanced its pipeline with key pivotal study starts and positive clinical trial results.
Bearish
Pfizer experienced operational revenue declines in 2025, driven by lower COVID-19 product sales and incurred $4.4 billion in asset impairment charges. The company also anticipates future revenue impacts from LOE and drug pricing policies.